Table 3.
The distribution of molecular subtypes of breast carcinomas by immunohistochemistry in various regional & western countries.
| Variables | Mehdi et al. | Yang et al. | Cheng et al. | Vallejos et al. | Fourati et al. | Carey et al. African American |
Carey et al. Non-African American |
Riyadh | Jeddah |
|---|---|---|---|---|---|---|---|---|---|
| Setting | Oman | Poland | China | Peru | Tunisia | California, USA | Saudi Arabia | ||
| Number of patients | 452 | 804 | 628 | 1198 | 966 | 196 | 300 | 357 | 740 |
| Years | 2006–2010 | 2000–2003 | 2007–2010 | 2000–2002 | 2007–2009 | 1993–1996 | 1993–1996 | 2010–2014 | 2012–2018 |
| Luminal A | 34.7% | 69.0% | 46.5% | 49.3% | 50.7% | 47.4% | 54.0% | 58.5% | 58.5% |
| Luminal B | 15.9% | 6.0% | 17.0% | 13.% | 13.4% | 12.7% | 17.3% | 14.5% | 14% |
| HER2/NEU | 24.1% | 8.0% | 15.0% | 16.2% | 13.4% | 8.2% | 5.6% | 12.3% | 11.5% |
| Triple negative | 25.3% | 18.0% | 21.5% | 21.3% | 22.5% | 31.6% | 23.0% | 14.8% | 16% |